
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5717324/publications.pdf Version: 2024-02-01



Ινίσα Ν Οιίμα

#	Article	IF	CITATIONS
1	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	6.1	19
2	Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. Hepatology, 2022, 75, 369-378.	3.6	12
3	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	3.6	107
4	Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection. Frontiers in Digital Health, 2022, 4, 737729.	1.5	3
5	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	1.3	2
6	Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. Biomedicines, 2022, 10, 477.	1.4	4
7	Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. Journal of Hepatology, 2022, 77, 365-376.	1.8	20
8	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clinical Gastroenterology and Hepatology, 2022, 20, 2567-2576.e6.	2.4	80
9	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 2022, 6, 1213-1226.	2.0	9
10	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	2.4	25
11	Addition of hyaluronic acid to the FIBâ€4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obesity Science and Practice, 2021, 7, 497-508.	1.0	2
12	Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. Journal of Pathology: Clinical Research, 2021, 7, 471-481.	1.3	8
13	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Reports, 2021, 3, 100384.	2.6	10
14	Validation of the AASLD recommendations for classification of oesophageal varices in clinical practice. Liver International, 2020, 40, 905-912.	1.9	10
15	Editorial: blood biomarkers for advanced liver fibrosis in nonâ€alcoholic fatty liver disease—not a simple choice?. Alimentary Pharmacology and Therapeutics, 2020, 51, 179-180.	1.9	1
16	Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. Public Health in Practice, 2020, 1, 100033.	0.7	4
17	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	1.8	158
18	Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterology, 2020, 11, 86-92.	0.9	45

#	Article	IF	CITATIONS
19	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology, 2020, 159, 1276-1289.e7.	0.6	53
20	Nonâ€invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. Liver International, 2020, 40, 2252-2262.	1.9	14
21	Detecting chronic liver disease: are liver function tests the solution?. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-8.	0.2	2
22	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	3.7	411
23	Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. BMJ Open, 2020, 10, e041574.	0.8	5
24	ADAPT: An Algorithm Incorporating PRO 3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology, 2019, 69, 1075-1086.	3.6	174
25	SAT-032-Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease specific complications. Journal of Hepatology, 2019, 70, e640.	1.8	0
26	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology, 2019, 71, 1141-1151.	1.8	104
27	Time to endoscopy for acute upper gastrointestinal bleeding: Results from a prospective multicentre traineeâ€led audit. United European Gastroenterology Journal, 2019, 7, 199-209.	1.6	25
28	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health, 2019, 22, 693-703.	0.1	13
29	Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. Clinical Gastroenterology and Hepatology, 2019, 17, 2330-2338.e1.	2.4	39
30	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 156, 1717-1730.	0.6	777
31	Acceptability to patients of screening disposable transnasal endoscopy: qualitative interview analysis. BMJ Open, 2019, 9, e030467.	0.8	8
32	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. American Journal of Gastroenterology, 2019, 114, 1744-1752.	0.2	32
33	Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. Clinical Gastroenterology and Hepatology, 2019, 17, 638-646.e1.	2.4	30
34	The effects of terlipressin and direct portacaval shunting on liver hemodynamics following 80% hepatectomy in the pig. Clinical Science, 2019, 133, 153-166.	1.8	7
35	Using MRI to study the alterations in liver blood flow, perfusion, and oxygenation in response to physiological stress challenges: Meal, hyperoxia, and hypercapnia. Journal of Magnetic Resonance Imaging, 2019, 49, 1577-1586.	1.9	10
36	Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. European Radiology, 2019, 29, 3100-3107.	2.3	11

#	Article	IF	CITATIONS
37	Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology, 2018, 73, 90-100.	1.6	13
38	Analysis of genotyping for predicting liver injury marker, procollagen <scp>III</scp> in persons at risk of nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 1832-1838.	1.9	2
39	Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective multicenter UK study. Journal of Hepatology, 2018, 68, S552-S553.	1.8	1
40	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a crossâ€sectional study using transient elastography. Alimentary Pharmacology and Therapeutics, 2018, 47, 504-515.	1.9	49
41	Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 25-36.	3.7	113
42	Transient elastography can stratify patients with Child–Pugh A cirrhosis according to risk of early decompensation. European Journal of Gastroenterology and Hepatology, 2018, 30, 1434-1440.	0.8	7
43	MRI assessment of altered dynamic changes in liver haemodynamics following a meal challenge in compensated cirrhosis. European Radiology Experimental, 2018, 2, .	1.7	6
44	SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Scientific Reports, 2018, 8, 17905.	1.6	30
45	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. United European Gastroenterology Journal, 2018, 6, 1372-1379.	1.6	5
46	Performance of controlled attenuation parameter (CAP) to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2018, 68, S98.	1.8	0
47	Magnetic Resonance Imaging Methods for Assessing Cirrhosis and Portal Hypertension. , 2018, , 211-223.		Ο
48	Nonâ€invasive tests for the detection of oesophageal varices in compensated cirrhosis: systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 806-818.	1.6	13
49	Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. Journal of Hepatology, 2018, 69, 1015-1024.	1.8	38
50	Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. The Lancet Gastroenterology and Hepatology, 2017, 2, 288-297.	3.7	138
51	<scp>SOX</scp> 9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. EMBO Molecular Medicine, 2017, 9, 1696-1710.	3.3	38
52	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open, 2017, 7, e015659.	0.8	50
53	Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 107-115.	0.6	15
54	The effect of prone positioning with surgical bolsters on liver blood flow in healthy volunteers. Anaesthesia, 2016, 71, 550-555.	1.8	11

#	Article	IF	CITATIONS
55	Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology and Hepatology, 2016, 1, 256-260.	3.7	131
56	Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. Journal of Hepatology, 2016, 65, 1131-1139.	1.8	87
57	Biomarkers of liver fibrosis. Clinical Liver Disease, 2016, 7, 139-142.	1.0	7
58	The detection of oesophageal varices using a novel, disposable, probeâ€based transnasal endoscope: a prospective diagnostic pilot study. Liver International, 2016, 36, 1639-1648.	1.9	10
59	Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 249-256.	0.2	12
60	The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart, 2015, 2, e000272.	0.9	51
61	A study of <i>T</i> ₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR in Biomedicine, 2015, 28, 706-714.	1.6	100
62	Tu1529 Superior Patient Preference and High Diagnostic Accuracy for the Detection of Barrett's Esophagus Using a Novel, Portable, Probe-Based TransNasal Endoscope. Gastrointestinal Endoscopy, 2015, 81, AB497-AB498.	0.5	0
63	Î ³ -Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia, 2015, 58, 1484-1493.	2.9	13
64	REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMJ Open, 2015, 5, e007700-e007700.	0.8	28
65	Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis. Biomedical Optics Express, 2015, 6, 1209.	1.5	10
66	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open, 2015, 5, e007516-e007516.	0.8	86
67	Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. Gastrointestinal Endoscopy, 2015, 82, 782-792.	0.5	48
68	Metabolic Phenotyping for Enhanced Mechanistic Stratification of Chronic Hepatitis C-Induced Liver Fibrosis. American Journal of Gastroenterology, 2015, 110, 159-169.	0.2	29
69	Non-invasive monitoring of liver fibrosis. British Medical Bulletin, 2014, 112, 97-106.	2.7	10
70	Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 2113-2120.e3.	2.4	24
71	Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. Journal of Hepatology, 2014, 60, 384-391.	1.8	63
72	Nonâ€invasive hepatic biomarkers (<scp>ELF</scp> and <scp>CK</scp> 18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver International, 2014, 34, 1267-1277.	1.9	7

#	Article	IF	CITATIONS
73	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology, 2013, 57, 103-111.	3.6	103
74	Structural and functional uncoupling of liver performance in the Fontan circulation. International Journal of Cardiology, 2013, 164, 77-81.	0.8	38
75	The performance of transient elastography compared to clinical acumen and routine tests – what is the incremental diagnostic value?. Liver International, 2013, 33, 172-179.	1.9	7
76	Were James Bond's drinks shaken because of alcohol induced tremor?. BMJ, The, 2013, 347, f7255-f7255.	3.0	16
77	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. European Journal of Gastroenterology and Hepatology, 2013, 25, 201-207.	0.8	14
78	Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comparative Hepatology, 2012, 11, 5.	0.9	27
79	Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology, 2012, 56, 1108-1116.	3.6	81
80	Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2011, 18, 23-31.	1.0	153
81	Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?. Hepatology, 2011, 54, 1454-1462.	3.6	48
82	Prediction, prevention and management of postresection liver failure. British Journal of Surgery, 2011, 98, 1188-1200.	0.1	168
83	Consistent beneficial effects of killer cell immunoglobulinâ€like receptor 2DL3 and group 1 human leukocyte antigen following exposure to hepatitis C virus. Hepatology, 2010, 51, 1168-1175.	3.6	145
84	Antibiotic prophylaxis in variceal hemorrhage: Timing, effectiveness andClostridium difficilerates. World Journal of Gastroenterology, 2010, 16, 5317.	1.4	23
85	Back to the future with noninvasive biomarkers of liver fibrosis. Hepatology, 2009, 49, 9-11.	3.6	6
86	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 2008, 47, 455-460.	3.6	625
87	Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities. Clinics in Liver Disease, 2008, 12, 883-900.	1.0	35
88	Resolving fibrosis in the diseased liver: Translating the scientific promise to the clinic. International Journal of Biochemistry and Cell Biology, 2007, 39, 695-714.	1.2	43
89	Performance of serum marker panels for liver fibrosis in chronic hepatitis C. Journal of Hepatology, 2006, 44, 462-474.	1.8	217
90	Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut, 2006, 55, 1650-1660.	6.1	113

#	Article	IF	CITATIONS
91	Case report of an arterioportal fistula, presenting with accelerated decompensation and sepsis, twenty-six years after initial liver biopsy. Hepatology Research, 2005, 32, 252-255.	1.8	3
92	F2-isoprostanes and the liver. Prostaglandins and Other Lipid Mediators, 2003, 72, 73-84.	1.0	5